Ustekinumab Intravenous (Stelara®, Wezlana™)

Covers a single weight‑based IV induction dose of ustekinumab (Stelara®, Wezlana™) for adults (≥18) with moderately to severely active Crohn’s disease or ulcerative colitis and excludes maintenance or non‑FDA indications. Approval (30 days/one dose) requires prescription by or consultation with a gastroenterologist, documentation of diagnosis and patient weight, and meeting disease‑specific prior therapy/clinical criteria (for Crohn’s: ileocolonic resection, fistulas, prior systemic agent trial, current/prior corticosteroid use or corticosteroid contraindication; for UC: prior systemic agent trial or pouchitis with trial of antibiotic/probiotic/corticosteroid enema/mesalamine enema).

"Ustekinumab intravenous will be used as induction therapy (induction-only use required)."

Sign up to see full coverage criteria, indications, and limitations.